<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Oprelvekin</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Oprelvekin">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Oprelvekin</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Oprelvekin</b> is recombinant interleukin eleven (IL-11),<span class="mw-ref" id="cite_ref-pmid12784347_1-0"><a href="#cite_note-pmid12784347-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> a <span class="new">thrombopoietic growth factor</span> that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name <b>Neumega</b>.</p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Oprelvekin</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/oprelvekin.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/oprelvekin.html'" tppabs="https://www.drugs.com/monograph/oprelvekin.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">

<ul><li>C</li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>s.c. injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L03AC02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L03AC02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L03AC02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L03AC02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>&gt;80% (s.c. application)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>mainly renal</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>6.9 ± 1.7h</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">?</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145941-26-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145941-26-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145941-26-0" class="external text external">145941-26-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6971  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6971'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6971" class="external text external">6971</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00038  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00038'" tppabs="https://www.drugbank.ca/drugs/DB00038" class="external text external">DB00038</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=HM5641GA6F  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=HM5641GA6F'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=HM5641GA6F" class="external text external">HM5641GA6F</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201573'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201573" class="external text external">ChEMBL1201573</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>854</sub><span>H</span><sub>1411</sub><span>N</span><sub>253</sub><span>O</span><sub>235</sub><span>S</span><sub>2</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td>approx. 19,000 g/mol<span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=400663911&page2=Oprelvekin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=400663911&page2=Oprelvekin'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=400663911&page2=Oprelvekin" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemical,_pharmacological_and_marketing_data">Chemical, pharmacological and marketing data</h2></summary>
    
<p>IL-11 is a member of a family of human growth factors and is being produced in the bone marrow of healthy adults. Synonyms are:</p>
<ul><li>AGIF</li>
<li>Adipogenesis inhibitory factor</li>
<li>Interleukin-11 precursor.</li></ul>

<p>Oprelvekin is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 g/mol, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either <i>in vitro</i> or <i>in vivo</i>.</p>

<p>The primary hematopoietic activity of Neumega is stimulation of megakaryocytopoiesis and thrombopoiesis.<span class="mw-ref" id="cite_ref-pmid18020592_2-0"><a href="#cite_note-pmid18020592-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In mice and nonhuman primate studies Neumega has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega improved platelet nadirs and accelerated platelet recoveries compared to controls.</p>

<p>In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines. However, pathologic changes, some also seen in humans, have been noticed:</p>

<ul><li>papilledema</li>
<li>fibrosis of tendons and joint capsules</li>
<li>periostal thickening and</li>
<li>embryotoxicity (see under pregnancy).</li></ul>

<p>In preclinical human trials mature megakaryocytes which develop during <i>in vivo</i> treatment with Neumega were ultrastructurally, morphologically, and functionally normal. They also showed a normal life span.</p>

<p>In a study in which a single 50<span>&nbsp;</span>µg/kg subcutaneous dose was administered to eighteen healthy men, the peak serum concentration (Cmax) of 17.4 ± 5.4<span>&nbsp;</span>ng/mL was reached at 3.2 ± 2.4 h (Tmax) following dosing. The terminal half-life was 6.9 ± 1.7 h. In a second study in which single 75<span>&nbsp;</span>µg/kg subcutaneous and intravenous doses were administered to twenty-four healthy subjects, the pharmacokinetic profiles were similar between men and women. The absolute bioavailability of Neumega was &gt;80%. In a study in which multiple, subcutaneous doses of both 25 and 50<span>&nbsp;</span>µg/kg were administered to cancer patients receiving chemotherapy, Neumega did not accumulate and clearance of Neumega was not altered following multiple doses. Pediatric cancer patients treated with aggressive chemotherapy showed similar pharmakinetic characteristics.</p>

<p>In humans treated with Oprelvekin on a daily base a twofold increase in fibrinogen levels occurred. Healthy volunteers displayed an increase in von-Willebrand-factor (vWf) activity. Isolated molecules formed under Oprelvekin were found to have exact the same multimere structure as the 'normal' factor and were therefore fully functioning. These increases in coagulation factors may contribute to the development of stroke (see under side-effects), but a precise association cannot be made at this stage.</p>

<p>In a variety of clinical studies upon which FDA approval is based, Neumega showed effectivity in reducing thrombocytopenia in oncologic patients treated with myelosuppressant chemotherapeutic drugs as measured by significantly decreased need of platelet transfusions.</p>
    
<p>Neumega is manufactured and sold by Wyeth. The drug is formulated in single-use vials containing 5<span>&nbsp;</span>mg of oprelvekin (specific activity approximately 8 × 106  Units/mg) as a sterile, lyophilized powder. The FDA approved the drug in 1997.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Indications">Indications</h2></summary>
    
<p>Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy was demonstrated in patients who had experienced severe thrombocytopenia following the previous chemotherapy cycle.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications_and_precautions">Contraindications and precautions</h2></summary>
    
<ul><li>Patients with known hypersensitivity to Oprelvekin itself or any other ingredient.</li>
<li>Patients with severe or decompensated heart failure should not be treated, because Oprelvekin may cause excessive fluid retention with edema and cardiac decompensation. Patients with compensated heart disease should be treated with caution and under permanent clinical supervision.</li>
<li>Neumega is not indicated following <span class="new">myeloablative chemotherapy</span> (increased likelihood of severe side-effects) and in pediatric patients.</li>
<li>Renal impairment<span>&nbsp;</span>:  Neumega is excreted renally. No differences of pharmakinetic parameters and clinical differences have been seen in mild to moderate impairment. Severe impairment has led to an increased number of patients with reduced hemoglobin due to dilutional anemia. Patients with severely disturbed renal function should be monitored very closely.</li>
<li>The efficacy of Oprelvekin has not been systematically studied in patients receiving chemotherapy regimes of more than 5 days duration/each cycle or in those regimes containing agents that induce delayed thrombocytopenia (e.g. nitrosoureas, mitomycin C. Neumega should not be given in these cases.</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pregnancy">Pregnancy</h2></summary>
    
<p>In studies with rats and rabbits treated chronically, Oprelvekin showed embryo- and fetotoxicity (early death of embryos and reduction of number of fetus, fetal malformations etc.). There is no sufficient human data available. Pregnant women should only be treated, if the benefit to the mother outweighs the potential risk to the unborn.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Lactation">Lactation</h2></summary>
    
<p>No human data is available if the drug is distributed into human milk. Nursing women should either discontinue breast-feeding or Neumega, the decision should take into account the importance of the drug to the mother.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>Neumega has caused allergic reaction which at times have been very serious. Symptoms have been edema of the face and tongue, or larynx; shortness of breath; wheezing; chest pain; hypotension (including shock); dysarthria; loss of consciousness, rash, urticaria, <a href="Flushing_(physiology).htm" tppabs="https://ptable.com/wiki/compounds/A/Flushing_(physiology)" title="Flushing (physiology)">flushing</a>, and fever. These reaction can occur after the first dose or after any later application. Neumega should be permanently discontinued in patients with any sign of allergy. Treatment is largely symptomatic.</p>

<p>Oprelvekin also has caused quite often fluid retention, ranging from peripheral edema (approximately 40% of patients) to dyspnea and full developed lung edema with or without cardiac decompensation (see contraindications and precautions). These symptoms have led to some deaths. Fluid retention my also lead to dilutional anemia (in 10 to 15% of patients). Hypokalemia my also result. Symptoms of fluid retention have been observed more often in patients following <span class="new">myeloablative chemotherapy</span> (see contraindications). Severe arrhythmias (atrial flutter and atrial fibrillation) as well as fatal cardiac arrest have also been seen which may or may be not attributed to fluid retention/increased volume. Isolated cases of stroke have been noted, those patients with previous transient ischemic attacks or partial/minor strokes may be at particular risk.</p>

<p>Papilledema of the eyes has been observed (2%) and may lead to disturbed visual acuity and even temporary or permanent blindness. Patients with preexisting papilledema or with involvement of the central nervous system may be at higher risk.</p>

<p>In postmarketing studies isolated cases of severe ventricular arrhythmias and renal failure have been seen.</p>

<p>Injection site reaction like have also been observed (dermatitis, pain, and discoloration), but are usually mild.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>The concomitant application of GM-CSFs such as <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">filgrastim</a> or <a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a> showed no potential interactions. Additionally, no other interactions are known. Interactions with drugs undergoing P450 enzyme metabolism are not likely to occur.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Necessary_examinations_during_treatment">Necessary examinations during treatment</h2></summary>
    
<p>Complete blood counts should be obtained before starting chemotherapy and in short intervals afterwards. Platelet counts should be done at the time of expected nadir (lowest number of platelets) and at least until remission starts (platelet counts greater than 50,000). The patients should be watched for signs of allergy, fluid retention and anemia during and after therapy with Neumega. Preexisting ascites and pericardial effusions should be monitored closely for signs of worsening.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Dosage_regimen">Dosage regimen</h2></summary>
    
<p>The dosage in patients without severe renal impairment is 50<span>&nbsp;</span>µg/kg subcutaneously once a day either abdominal, in thigh, or hip. Most patients will be able to self-administer the drug after appropriate training.</p>

<p>Patients with severe renal impairment should receive only 25<span>&nbsp;</span>µg/kg daily.</p>

<p>The first dose should be given 6 to 24 hours after completion of chemotherapy. Dosing should be continued until platelet counts reach at least 50,000 cells. Usually, one course of Neumega encompasses 10 to 21 days.</p>

<p>The drug should be discontinued at least 2 days before starting the next chemotherapy cycle.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Additional_information">Additional information</h2></summary>
    
<p>Neumega vials must be stored in a refrigerator at 2 to 8 C (36 to 46 F). Protect from light. Do not freeze.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="mw-references-wrap"><ol class="mw-references references"><li id="cite_note-pmid12784347-1"> <span id="mw-reference-text-cite_note-pmid12784347-1" class="mw-reference-text"><cite id="CITEREFCantorEltingHudsonRubenstein2003" class="citation journal cs1">Cantor SB, Elting LS, Hudson DV, Rubenstein EB (June 2003). "Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy". <i>Cancer</i>. <b>97</b> (12): 3099–106. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcncr.11447  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcncr.11447'" tppabs="https://doi.org/10.1002%2Fcncr.11447" class="external text external">10.1002/cncr.11447</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12784347  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12784347'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12784347" class="external text external">12784347</a>.</cite></span></li><li id="cite_note-pmid18020592-2"> <span id="mw-reference-text-cite_note-pmid18020592-2" class="mw-reference-text"><cite id="CITEREFWildeFaulds1998" class="citation journal cs1">Wilde MI, Faulds D (August 1998). "Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia". <i>BioDrugs</i>. <b>10</b> (2): 159–71. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00063030-199810020-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00063030-199810020-00006'" tppabs="https://doi.org/10.2165%2F00063030-199810020-00006" class="external text external">10.2165/00063030-199810020-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18020592  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18020592'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18020592" class="external text external">18020592</a>.</cite></span></li></ol></div>
<ul><li><a href="javascript:if(confirm('http://www.rxlist.com/cgi/generic3/oprelvek.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rxlist.com/cgi/generic3/oprelvek.htm'" tppabs="http://www.rxlist.com/cgi/generic3/oprelvek.htm" class="external free external">http://www.rxlist.com/cgi/generic3/oprelvek.htm</a></li>
<li><a href="javascript:if(confirm('http://www.wyeth.com/products_hcp?product=/wyeth_html/home/products/prescription/Neumega®%20(oprelvekin)/Neumega®%20(oprelvekin)_overview.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wyeth.com/products_hcp?product=/wyeth_html/home/products/prescription/Neumega®%20(oprelvekin)/Neumega®%20(oprelvekin)_overview.html'" tppabs="http://www.wyeth.com/products_hcp?product=/wyeth_html/home/products/prescription/Neumega®%20(oprelvekin)/Neumega®%20(oprelvekin)_overview.html" class="external free external">http://www.wyeth.com/products_hcp?product=/wyeth_html/home/products/prescription/Neumega®%20(oprelvekin)/Neumega®%20(oprelvekin)_overview.html</a> (Drug Information provided by Wyeth)</li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunostimulants_(L03)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunostimulants_(L03)" style="font-size:114%;margin:0 4em">Immunostimulants (L03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cytokines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Colony-stimulating factors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>G-CSF
<ul><li><a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a> / Lipegfilgrastim / <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li>Lenograstim</li>
<li><i>Eflapegrastim</i></li></ul></li>
<li>GM-CSF
<ul><li>Molgramostim</li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul></li>
<li>SCF
<ul><li>Ancestim</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferons</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>alpha</i>:
<ul><li>Albinterferon</li>
<li>Interferon alfa natural</li>
<li><span class="new">Interferon alfa 2a</span> / Peginterferon alfa-2a</li>
<li>Interferon alfa 2b / Peginterferon alfa-2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li></ul></li>
<li><i>beta</i>:
<ul><li>Interferon beta natural</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li></ul></li>
<li>Interferon gamma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukins</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Aldesleukin</a></li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other protein / peptide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Immunocyanin</li>
<li><a href="Adenosine_deaminase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegademase" title="Pegademase" class="mw-redirect">Pegademase</a></li>
<li>Prolactin</li>
<li>Tasonermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Female sex steroids</li>
<li><a href="Histamine_dihydrochloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine_dihydrochloride" title="Histamine dihydrochloride">Histamine dihydrochloride</a></li>
<li>Poly ICLC</li>
<li><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Vitamin D</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>beta-glucan
<ul><li>Lentinan</li></ul></li>
<li>heterocyclic compound
<ul><li>Plerixafor</li></ul></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">hydroxyquinoline</a>
<ul><li>Roquinimex</li></ul></li>
<li>Mifamurtide</li>
<li>oligopeptides
<ul><li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li>Thymopentin</li>
<li>Thymosin α1</li>
<li>Thymulin</li></ul></li>
<li>polyribonucleotide
<ul><li>Polyinosinic:polycytidylic acid</li></ul></li>
<li><a href="Thiazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidine" title="Thiazolidine">thiazolidine</a>
<ul><li><a href="Pidotimod.htm" tppabs="https://ptable.com/wiki/compounds/A/Pidotimod" title="Pidotimod">Pidotimod</a></li></ul></li>
<li>vaccines
<ul><li>Bacillus Calmette–Guérin</li>
<li>Melanoma vaccine</li>
<li>Sipuleucel-T</li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Interleukin_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Interleukin_receptor_modulators" style="font-size:114%;margin:0 4em">Interleukin receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 1 (α, β)</li>
<li><span class="new">Mobenakin</span></li>
<li><span class="new">Pifonakin</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">AF-12198</span></li>
<li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li>
<li>IL-1RA</li>
<li><span class="new">Isunakinra</span></li></ul>

<ul><li><i>Antibodies:</i> Canakinumab</li>
<li>Gevokizumab</li>
<li><span class="new">Lutikizumab</span></li></ul>

<ul><li><i>Decoy receptors:</i> Rilonacept (IL-1 Trap)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Adargileukin alfa</span></li>
<li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldesleukin" title="Aldesleukin" class="mw-redirect">Aldesleukin</a></li>
<li><span class="new">Celmoleukin</span></li>
<li><a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a></li>
<li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Interleukin 2</a></li>
<li><span class="new">Pegaldesleukin</span></li>
<li><span class="new">Teceleukin</span></li>
<li>Tucotuzumab celmoleukin</li></ul>

<ul><li><i>Antibodies:</i> <a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab (dacliximab)</a></li>
<li>Inolimomab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Daniplestim</span></li>
<li>Interleukin 3</li>
<li><span class="new">Leridistim</span></li>
<li><span class="new">Milodistim</span></li>
<li><span class="new">Muplestim</span></li>
<li>Promegapoietin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Binetrakin</span></li>
<li>Interleukin 4</li>
<li>Interleukin 13</li></ul>

<ul><li><i>Antagonists:</i> Pitrakinra</li></ul>

<ul><li><i>Antibodies:</i> Dupilumab</li>
<li>Pascolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-5</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 5</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">YM-90709</span></li></ul>

<ul><li><i>Antibodies:</i> Benralizumab</li>
<li>Mepolizumab</li>
<li>Reslizumab</li></ul>

<ul><li><i>Antisense oligonucleotides:</i> <span class="new">TPI ASM8</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-6</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Atexakin alfa</span></li>
<li>Interleukin 6</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">ARGX-109</span></li>
<li>Clazakizumab</li>
<li>Elsilimomab</li>
<li><span class="new">mAb 1339</span></li>
<li>Olokizumab</li>
<li>Sarilumab</li>
<li>Siltuximab</li>
<li>Sirukumab</li>
<li>Tocilizumab</li>
<li><span class="new">Levilimab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-7</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 7</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-8</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-9</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 9</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Enokizumab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-10</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ilodecakin</span></li>
<li>Interleukin 10 (CSIF)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-11</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 11 (AGIF)</li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-12</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Edodekin alfa</span></li>
<li>Interleukin 12</li></ul>

<ul><li><i>Antibodies:</i> Briakinumab</li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-13</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Binetrakin</span></li>
<li><span class="new">Cintredekin besudotox</span></li>
<li>Interleukin 4</li>
<li>Interleukin 13</li></ul>

<ul><li><i>Antibodies:</i> Anrukinzumab</li>
<li>Lebrikizumab</li>
<li>Tralokinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-15</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> ALT-803</li>
<li>Interleukin 15</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-17</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 17 (A, <span class="new">B</span>, <span class="new">C</span>, <span class="new">D</span>, E (interleukin 25), <span class="new">F</span>)</li></ul>

<ul><li><i>Antibodies:</i> Brodalumab</li>
<li>Ixekizumab</li>
<li>Perakizumab</li>
<li><span class="new">Remtolumab</span></li>
<li>Secukinumab</li>
<li><span class="new">Vunakizumab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-18</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Iboctadekin</span></li>
<li>Interleukin 18</li>
<li>Interleukin 37</li>
<li><span class="new">Tadekinig</span></li></ul>

<ul><li><i>Binding proteins:</i> IL18BP</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-20</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 19</li>
<li>Interleukin 20</li>
<li>Interleukin 24</li></ul>

<ul><li><i>Antibodies:</i> Fletikumab (against IL-20)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-21</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Denenicokin</span></li>
<li>Interleukin 21</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">NNC0114-0005</span></li>
<li><span class="new">NNC0114-0006</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-22</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 22</li></ul>

<ul><li><i>Antibodies:</i> Fezakinumab (against IL-22)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-23</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 23 (SGRF)</li></ul>

<ul><li><i>Antibodies:</i> Brazikumab</li>
<li>Briakinumab</li>
<li>Guselkumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-27</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 27 (interleukin 30)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-28</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Interferon λ4 (IFN-λ4)</span></li>
<li>Interleukin 28 (<span class="new">A (IFN-λ2)</span>, B (IFN-λ3))</li>
<li>Interleukin-29 (IFN-λ1)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-31</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 31</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL1RL1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 33</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL1RL2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 36 (α, β, γ)</li>
<li>Interleukin 38</li></ul>

<ul><li><i>Antagonists:</i> IL-36RA</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Interleukin 14 (taxilin alpha, HMW-BCGF)</li>
<li>Interleukin 16 (signals through CD4)</li>
<li>Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer)</li>
<li>Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer)</li>
<li>Interleukin 32</li>
<li>Interleukin 34 (signals through M-CSFR/CSF1R)</li>
<li>Interleukin 35</li></ul>

<ul><li><i>Unsorted:</i> <span class="new">Efavaleukin alfa</span></li>
<li><span class="new">Efineptakin alfa</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>





<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>